TRIFEXIS™ (spinosad + milbemycin oxime)
Chewable Tablets
Before using TRIFEXIS chewable tablets, please consult the product insert, a summary of which follows:
Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Indications:
TRIFEXIS is indicated for the prevention of heartworm disease ( immitis ), and the treatment and control of adult hookworm (), adult roundworm ( and ) and adult whipworm ( ) infections in dogs and puppies 8 weeks of age or older and 5 pounds of body weight or greater.
Contraindications: There are no known contraindications to the use of TRIFEXIS Chewable Tablets.
Warnings: Not for human use. Keep this and all drugs out of the reach of children.
Serious adverse reactions have been reported following concomitant extra-label use of ivermectin with spinosad alone, one of the components of TRIFEXIS Chewable Tablets (see ADVERSE REACTIONS).
Precautions: Treatment with fewer than 3 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention (see EFFECTIVENESS).
Prior to administration of TRIFEXIS, dogs should be tested for existing heartworm infection. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. TRIFEXIS . While the number of circulating as labored respiration, vomiting, salivation and lethargy, have been noted in some dogs treated with milbemycin oxime carrying a high number of
Use with caution in breeding females. The safe use of TRIFEXIS in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy. Puppies less than 14 weeks of age may experience a higher rate of vomiting.
Adverse Reactions: (176 treated with TRIFEXIS chewable tablets and 176 treated with an active control), no serious adverse reactions were attributed to administration of TRIFEXIS chewable tablets. All reactions were regarded as mild.
Reactions that occurred at an incidence >2% (average monthly rate) within any of the 6 months of observation are presented in the following table:
Average Monthly Rate (%) of Dogs With Adverse Reactions Adverse
Reaction Vomiting Pruritus Lethargy Diarrhea
a n=176 dogs
mild seizure 2½ hours after receiving the second monthly dose. The dog remained enrolled and received four additional monthly doses after the event and completed the study without further incident.
Following concomitant extra-label use of ivermectin with spinosad alone, a component of TRIFEXIS, some dogs have experienced the following clinical signs: . Spinosad alone has been shown to be safe when administered concurrently with heartworm preventatives at label directions.
with spinosad alone at the therapeutic dose range of 13.5-27.3 mg/lb (30-60 mg/kg), including 4 dogs with pre-existing epilepsy. Four epileptic dogs that received higher than the maximum recommended dose of 27.3 mg/lb (60 mg/kg) experienced at least one seizure within the week be determined.
For technical assistance or to report an adverse drug reaction, call 1-888-545-5973. Additional information can be found at
www.TRIFEXIS.com.
induced heartworm infections when administered for 3 consecutive monthly against heartworm infection. In another well-controlled laboratory study, a TRIFEXIS, no dogs were positive for heartworm infection as determined by heartworm antigen testing performed at the end of the study and again three months later.
In a well-controlled laboratory study, TRIFEXIS demonstrated 100% on Day 30. In a well-controlled laboratory study, spinosad, a component reductions of 98.0% to 99.8% were observed over the course of 3 monthly showed improvement in erythema, papules, scaling, alopecia, dermatitis/
removing naturally and experimentally induced adult roundworm, whipworm and hookworm infections.
NADA #141-321, Approved by the FDA
Manufactured for Elanco Animal Health A Division of Eli Lilly & Co. Lilly Corporate Center, Indianapolis, IN 46285
Trifexis™ is a trademark of Eli Lilly and Company Trends magazine, April 2012 PA9945DEAMX (V01-12-2010) WEWANT TO HEAR FROM YOU!
Please let us know your sugges- tions for improving Trends.
Email us at trendstoday@aahanet. org or send letters to:
Trends, AAHA, 12575 West Bayaud Avenue, Lakewood, CO 80228
TRIFEXIS Chewable Tabletsa
6.13 4.00 2.63 2.25
Active Control Tabletsa
3.08 4.91 1.54 1.54
READERS’ RESPONSES TO TRENDS MAGAZINE
speakout Why don’t more hospitals take the
AAHA challenge and benefit from this organization’s tremendous experience and resources? What do they have to fear? To all my readers who have yet to lift the well-organized (and maybe daunting?) book of AAHA requirements and recommendations, can I please make a plea to try it? I am telling you earnestly from my experience: I can think of noth- ing else that proves to be such a perfect tool to rally your entire team’s interest and energy. Even if you choose never to invite AAHA’s experienced practice consultants to your practice (and what a disservice you would be doing yourself and your practice team if you didn’t... these people are here to HELP, not to pick you apart), I can assure you that the AAHA accreditation standards and recommendations are the perfect count- down checklist to your practice’s blastoff to higher goals.
Bash Halow, Halow Consulting
From a blog post on
halowconsulting.blogspot.com on Jan. 7, 2012. Used with permission.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68